Gene and cell-based therapies for heart disease

Luis G. Melo, Alok S. Pachori, Deling Kong, Massimiliano Gnecchi, Kai Wang, Richard E. Pratt, Victor J. Dzau

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Heart disease remains the prevalent cause of premature death and accounts for a significant proportion of all hospital admissions. Recent developments in understanding the molecular mechanisms of myocardial disease have led to the identification of new therapeutic targets, and the availability of vectors with enhanced myocardial tropism offers the opportunity for the design of gene therapies for both protection and rescue of the myocardium. Genetic therapies have been devised to treat complex diseases such as myocardial ischemia, heart failure, and inherited myopathies in various animal models. Some of these experimental therapies have made a successful transition to clinical trial and are being considered for use in human patients. The recent isolation of endothelial and cardiomyocyte precursor cells from adult bone marrow may permit the design of strategies for repair of the damaged heart. Cell-based therapies may have potential application in neovascularization and regeneration of ischemic and infarcted myocardium, in blood vessel reconstruction, and in bioengineering of artificial organs and prostheses. We expect that advances in the field will lead to the development of safer and more efficient vectors. The advent of genomic screening technology should allow the identification of novel therapeutic targets and facilitate the detection of disease-causing polymorphisms that may lead to the design of individualized gene and cell-based therapies.

Original languageEnglish
Pages (from-to)648-663
Number of pages16
JournalFASEB Journal
Volume18
Issue number6
DOIs
Publication statusPublished - Apr 2004

Fingerprint

heart diseases
Cell- and Tissue-Based Therapy
Genetic Therapy
Heart Diseases
Myocardium
Genes
Artificial Organs
Bioengineering
therapeutics
Investigational Therapies
Premature Mortality
Tropism
Muscular Diseases
Cardiomyopathies
Cardiac Myocytes
Bone Marrow Cells
Prostheses and Implants
Myocardial Ischemia
Blood Vessels
Regeneration

Keywords

  • AAV
  • Contractile function
  • Coronary artery disease
  • Myocardial protection

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Melo, L. G., Pachori, A. S., Kong, D., Gnecchi, M., Wang, K., Pratt, R. E., & Dzau, V. J. (2004). Gene and cell-based therapies for heart disease. FASEB Journal, 18(6), 648-663. https://doi.org/10.1096/fj.03-1171rev

Gene and cell-based therapies for heart disease. / Melo, Luis G.; Pachori, Alok S.; Kong, Deling; Gnecchi, Massimiliano; Wang, Kai; Pratt, Richard E.; Dzau, Victor J.

In: FASEB Journal, Vol. 18, No. 6, 04.2004, p. 648-663.

Research output: Contribution to journalArticle

Melo, LG, Pachori, AS, Kong, D, Gnecchi, M, Wang, K, Pratt, RE & Dzau, VJ 2004, 'Gene and cell-based therapies for heart disease', FASEB Journal, vol. 18, no. 6, pp. 648-663. https://doi.org/10.1096/fj.03-1171rev
Melo LG, Pachori AS, Kong D, Gnecchi M, Wang K, Pratt RE et al. Gene and cell-based therapies for heart disease. FASEB Journal. 2004 Apr;18(6):648-663. https://doi.org/10.1096/fj.03-1171rev
Melo, Luis G. ; Pachori, Alok S. ; Kong, Deling ; Gnecchi, Massimiliano ; Wang, Kai ; Pratt, Richard E. ; Dzau, Victor J. / Gene and cell-based therapies for heart disease. In: FASEB Journal. 2004 ; Vol. 18, No. 6. pp. 648-663.
@article{67fdc89fa5454028be05d0cf81cd9161,
title = "Gene and cell-based therapies for heart disease",
abstract = "Heart disease remains the prevalent cause of premature death and accounts for a significant proportion of all hospital admissions. Recent developments in understanding the molecular mechanisms of myocardial disease have led to the identification of new therapeutic targets, and the availability of vectors with enhanced myocardial tropism offers the opportunity for the design of gene therapies for both protection and rescue of the myocardium. Genetic therapies have been devised to treat complex diseases such as myocardial ischemia, heart failure, and inherited myopathies in various animal models. Some of these experimental therapies have made a successful transition to clinical trial and are being considered for use in human patients. The recent isolation of endothelial and cardiomyocyte precursor cells from adult bone marrow may permit the design of strategies for repair of the damaged heart. Cell-based therapies may have potential application in neovascularization and regeneration of ischemic and infarcted myocardium, in blood vessel reconstruction, and in bioengineering of artificial organs and prostheses. We expect that advances in the field will lead to the development of safer and more efficient vectors. The advent of genomic screening technology should allow the identification of novel therapeutic targets and facilitate the detection of disease-causing polymorphisms that may lead to the design of individualized gene and cell-based therapies.",
keywords = "AAV, Contractile function, Coronary artery disease, Myocardial protection",
author = "Melo, {Luis G.} and Pachori, {Alok S.} and Deling Kong and Massimiliano Gnecchi and Kai Wang and Pratt, {Richard E.} and Dzau, {Victor J.}",
year = "2004",
month = "4",
doi = "10.1096/fj.03-1171rev",
language = "English",
volume = "18",
pages = "648--663",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Gene and cell-based therapies for heart disease

AU - Melo, Luis G.

AU - Pachori, Alok S.

AU - Kong, Deling

AU - Gnecchi, Massimiliano

AU - Wang, Kai

AU - Pratt, Richard E.

AU - Dzau, Victor J.

PY - 2004/4

Y1 - 2004/4

N2 - Heart disease remains the prevalent cause of premature death and accounts for a significant proportion of all hospital admissions. Recent developments in understanding the molecular mechanisms of myocardial disease have led to the identification of new therapeutic targets, and the availability of vectors with enhanced myocardial tropism offers the opportunity for the design of gene therapies for both protection and rescue of the myocardium. Genetic therapies have been devised to treat complex diseases such as myocardial ischemia, heart failure, and inherited myopathies in various animal models. Some of these experimental therapies have made a successful transition to clinical trial and are being considered for use in human patients. The recent isolation of endothelial and cardiomyocyte precursor cells from adult bone marrow may permit the design of strategies for repair of the damaged heart. Cell-based therapies may have potential application in neovascularization and regeneration of ischemic and infarcted myocardium, in blood vessel reconstruction, and in bioengineering of artificial organs and prostheses. We expect that advances in the field will lead to the development of safer and more efficient vectors. The advent of genomic screening technology should allow the identification of novel therapeutic targets and facilitate the detection of disease-causing polymorphisms that may lead to the design of individualized gene and cell-based therapies.

AB - Heart disease remains the prevalent cause of premature death and accounts for a significant proportion of all hospital admissions. Recent developments in understanding the molecular mechanisms of myocardial disease have led to the identification of new therapeutic targets, and the availability of vectors with enhanced myocardial tropism offers the opportunity for the design of gene therapies for both protection and rescue of the myocardium. Genetic therapies have been devised to treat complex diseases such as myocardial ischemia, heart failure, and inherited myopathies in various animal models. Some of these experimental therapies have made a successful transition to clinical trial and are being considered for use in human patients. The recent isolation of endothelial and cardiomyocyte precursor cells from adult bone marrow may permit the design of strategies for repair of the damaged heart. Cell-based therapies may have potential application in neovascularization and regeneration of ischemic and infarcted myocardium, in blood vessel reconstruction, and in bioengineering of artificial organs and prostheses. We expect that advances in the field will lead to the development of safer and more efficient vectors. The advent of genomic screening technology should allow the identification of novel therapeutic targets and facilitate the detection of disease-causing polymorphisms that may lead to the design of individualized gene and cell-based therapies.

KW - AAV

KW - Contractile function

KW - Coronary artery disease

KW - Myocardial protection

UR - http://www.scopus.com/inward/record.url?scp=1842559592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842559592&partnerID=8YFLogxK

U2 - 10.1096/fj.03-1171rev

DO - 10.1096/fj.03-1171rev

M3 - Article

VL - 18

SP - 648

EP - 663

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -